Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Shares Issued (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Shares Issued for 6 consecutive years, with $15000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Issued fell 60.53% year-over-year to $15000.0, compared with a TTM value of $28000.0 through Sep 2025, down 95.73%, and an annual FY2024 reading of $622000.0, up 16.26% over the prior year.
  • Shares Issued was $15000.0 for Q3 2025 at Ovid Therapeutics, up from $13000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $720718.0 in Q4 2021 and bottomed at -$43599.0 in Q4 2022.
  • Average Shares Issued over 5 years is $134767.9, with a median of $81629.0 recorded in 2022.
  • Peak annual rise in Shares Issued hit 3033.83% in 2021, while the deepest fall reached 118.59% in 2021.
  • Year by year, Shares Issued stood at $720718.0 in 2021, then plummeted by 106.05% to -$43599.0 in 2022, then skyrocketed by 175.69% to $33000.0 in 2023, then rose by 15.15% to $38000.0 in 2024, then plummeted by 60.53% to $15000.0 in 2025.
  • Business Quant data shows Shares Issued for OVID at $15000.0 in Q3 2025, $13000.0 in Q1 2025, and $38000.0 in Q3 2024.